• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

来自食品、人类和动物的耐萘啶酸大肠杆菌菌株中gyrA和parC基因的突变。

Mutations in gyrA and parC genes in nalidixic acid-resistant Escherichia coli strains from food products, humans and animals.

作者信息

Sáenz Yolanda, Zarazaga Myriam, Briñas Laura, Ruiz-Larrea Fernanda, Torres Carmen

机构信息

Area de Bioquímica y Biología Molecular, Universidad de La Rioja, Madre de Dios 51, 26006, Logroño, Spain.

出版信息

J Antimicrob Chemother. 2003 Apr;51(4):1001-5. doi: 10.1093/jac/dkg168. Epub 2003 Mar 13.

DOI:10.1093/jac/dkg168
PMID:12654733
Abstract

Mutations in quinolone targets were analysed in 80 unrelated nalidixic acid-resistant (NALR) Escherichia coli strains whose nalidixic acid and ciprofloxacin MICs ranged from 32 to >256 mg/L and 0.03-64 mg/L, respectively. These strains were isolated from food products (23) and faecal samples from humans (15) and healthy animals (42). Thirteen nalidixic acid-susceptible (NALS) E. coli strains were also analysed. Mutations in gyrA and parC genes were studied by PCR and sequencing. No amino acid changes were detected in GyrA or ParC proteins of the 13 NALS strains. A single change in the GyrA protein was detected in all 61 NALR strains with ciprofloxacin MICs </= 2 mg/L with the following substitutions (number of strains): Ser-83-->Leu (54), Ser-83-->Ala (one), Ser-83-->Val (one), Asp-87-->Asn (two), Asp-87-->Tyr (two) and Asp-87-->Gly (one). A double change in GyrA was found in 18 of 19 NALR strains with ciprofloxacin MICs >/= 4 mg/L. Amino acid substitutions were Ser-83-->Leu, with an additional change [Asp-87-->Asn (15), Asp-87-->Tyr (two) or Asp-87-->His (one)]. The remaining strain (ciprofloxacin MIC 4 mg/L) showed a single Ser-83-->Leu substitution. In respect of the ParC protein, a single change at Ser-80 or Glu-84 was found in 25 of 42 strains, with ciprofloxacin MICs ranging from 0.5 to 32 mg/L. A double substitution (Ser-80-->Ile and Glu-84-->Gly) was found in one strain (ciprofloxacin MIC 64 mg/L). No amino acid changes were detected in the GyrB protein of 18 NALR strains.

摘要

对80株无亲缘关系的耐萘啶酸(NALR)大肠杆菌菌株进行了喹诺酮靶点突变分析,这些菌株的萘啶酸和环丙沙星MIC分别为32至>256mg/L和0.03 - 64mg/L。这些菌株分离自食品(23株)以及人类(15株)和健康动物(42株)的粪便样本。还分析了13株萘啶酸敏感(NALS)大肠杆菌菌株。通过PCR和测序研究了gyrA和parC基因的突变。在13株NALS菌株的GyrA或ParC蛋白中未检测到氨基酸变化。在环丙沙星MIC≤2mg/L的所有61株NALR菌株中检测到GyrA蛋白有单一变化,替换情况如下(菌株数量):Ser-83→Leu(54株)、Ser-83→Ala(1株)、Ser-83→Val(1株)、Asp-87→Asn(2株)、Asp-87→Tyr(2株)和Asp-87→Gly(1株)。在环丙沙星MIC≥4mg/L的19株NALR菌株中的18株中发现GyrA有双重变化。氨基酸替换为Ser-83→Leu,并伴有额外变化[Asp-87→Asn(15株)、Asp-87→Tyr(2株)或Asp-87→His(1株)]。其余菌株(环丙沙星MIC 4mg/L)显示单一的Ser-83→Leu替换。关于ParC蛋白,在环丙沙星MIC为0.5至32mg/L的42株菌株中的25株中发现Ser-80或Glu-84有单一变化。在1株菌株(环丙沙星MIC 64mg/L)中发现双重替换(Ser-80→Ile和Glu-84→Gly)。在18株NALR菌株的GyrB蛋白中未检测到氨基酸变化。

相似文献

1
Mutations in gyrA and parC genes in nalidixic acid-resistant Escherichia coli strains from food products, humans and animals.来自食品、人类和动物的耐萘啶酸大肠杆菌菌株中gyrA和parC基因的突变。
J Antimicrob Chemother. 2003 Apr;51(4):1001-5. doi: 10.1093/jac/dkg168. Epub 2003 Mar 13.
2
[Mutations of gyrA in ciprofloxacin resistant Escherichia coli strains].[耐环丙沙星大肠杆菌菌株中gyrA基因的突变]
Mikrobiyol Bul. 2003 Apr-Jun;37(2-3):125-30.
3
The acquisition of full fluoroquinolone resistance in Salmonella Typhi by accumulation of point mutations in the topoisomerase targets.伤寒沙门氏菌通过拓扑异构酶靶点的点突变积累获得对氟喹诺酮类药物的完全耐药性。
J Antimicrob Chemother. 2006 Oct;58(4):733-40. doi: 10.1093/jac/dkl333. Epub 2006 Aug 8.
4
In vitro activity of sitafloxacin against clinical strains of Streptococcus pneumoniae with defined amino acid substitutions in QRDRs of gyrase A and topoisomerase IV.司帕沙星对肺炎链球菌临床菌株的体外活性,这些菌株在gyrase A和拓扑异构酶IV的喹诺酮耐药决定区(QRDRs)中有特定的氨基酸替代。
J Antimicrob Chemother. 2006 Dec;58(6):1279-82. doi: 10.1093/jac/dkl427. Epub 2006 Oct 20.
5
Detection of mutations in the gyrA and parC genes in quinolone-resistant clinical isolates of Enterobacter cloacae.阴沟肠杆菌喹诺酮耐药临床分离株中gyrA和parC基因突变的检测
J Antimicrob Chemother. 1997 Oct;40(4):543-9. doi: 10.1093/jac/40.4.543.
6
Infrequent occurrence of single mutations in topoisomerase IV and DNA gyrase genes among US levofloxacin-susceptible clinical isolates of Streptococcus pneumoniae from nine institutions (1999-2003).在美国九个机构(1999 - 2003年)对左氧氟沙星敏感的肺炎链球菌临床分离株中,拓扑异构酶IV和DNA促旋酶基因单突变的发生率较低。
J Antimicrob Chemother. 2006 Mar;57(3):437-42. doi: 10.1093/jac/dki487. Epub 2006 Jan 23.
7
Fluoroquinolone resistance and gyrA and parC mutations of Escherichia coli isolated from chicken.从鸡中分离的大肠杆菌的氟喹诺酮耐药性及gyrA和parC基因突变
J Microbiol. 2005 Oct;43(5):391-7.
8
Molecular characterization of ciprofloxacin-resistant Salmonella enterica serovar Typhi and Paratyphi A causing enteric fever in India.印度引起肠热症的耐环丙沙星肠炎沙门氏菌伤寒血清型和甲型副伤寒血清型的分子特征分析
J Antimicrob Chemother. 2006 Dec;58(6):1139-44. doi: 10.1093/jac/dkl391. Epub 2006 Oct 28.
9
Molecular basis of high-level ciprofloxacin resistance in Neisseria gonorrhoeae strains isolated in Denmark from 1995 to 1998.1995年至1998年在丹麦分离出的淋病奈瑟菌菌株中高水平环丙沙星耐药性的分子基础。
Antimicrob Agents Chemother. 2001 Jan;45(1):117-23. doi: 10.1128/AAC.45.1.117-123.2001.
10
In vivo selection during ofloxacin therapy of Escherichia coli with combined topoisomerase mutations that confer high resistance to ofloxacin but susceptibility to nalidixic acid.在氧氟沙星治疗期间,对大肠杆菌进行体内筛选,这些大肠杆菌具有组合拓扑异构酶突变,对氧氟沙星具有高抗性,但对萘啶酸敏感。
J Antimicrob Chemother. 2006 Nov;58(5):1054-7. doi: 10.1093/jac/dkl361. Epub 2006 Sep 19.

引用本文的文献

1
One day in Denmark: whole-genome sequence-based analysis of Escherichia coli isolates from clinical settings.丹麦的一天:基于全基因组序列的临床环境中大肠杆菌分离株分析
J Antimicrob Chemother. 2025 Apr 2;80(4):1011-1021. doi: 10.1093/jac/dkaf028.
2
Isolation, Characterization, and Complete Genome Sequence of Escherichia Phage KIT06 Which Infects Nalidixic Acid-Resistant .感染耐萘啶酸的大肠杆菌噬菌体KIT06的分离、特性鉴定及全基因组序列
Antibiotics (Basel). 2024 Jun 23;13(7):581. doi: 10.3390/antibiotics13070581.
3
Chance Favors the Prepared Genomes: Horizontal Transfer Shapes the Emergence of Antibiotic Resistance Mutations in Core Genes.
机遇偏爱有准备的基因组:水平转移塑造核心基因中抗生素耐药性突变的出现。
Mol Biol Evol. 2023 Oct 4;40(10). doi: 10.1093/molbev/msad217.
4
Quinolone-resistant Escherichia coli at the interface between humans, poultry and their shared environment- a potential public health risk.人类、家禽及其共享环境之间交界处的耐喹诺酮大肠杆菌——一种潜在的公共卫生风险。
One Health Outlook. 2023 Feb 28;5(1):2. doi: 10.1186/s42522-023-00079-0.
5
Chicken Production and Human Clinical Isolates Differ in Their Carriage of Antimicrobial Resistance and Virulence Factors.鸡生产和人类临床分离株在携带抗菌药物耐药性和毒力因子方面存在差异。
Appl Environ Microbiol. 2023 Feb 28;89(2):e0116722. doi: 10.1128/aem.01167-22. Epub 2023 Jan 18.
6
Antimicrobial resistance and genomic characterization of serovar Senftenberg isolates in production animals from the United States.美国生产动物中森夫滕贝格血清型分离株的抗菌药物耐药性及基因组特征
Front Microbiol. 2022 Nov 3;13:979790. doi: 10.3389/fmicb.2022.979790. eCollection 2022.
7
Investigation of In Vitro Susceptibility and Resistance Mechanisms in Skin Pathogens: Perspectives for Fluoroquinolone Therapy in Canine Pyoderma.皮肤病原体的体外药敏性及耐药机制研究:犬脓皮病中氟喹诺酮类药物治疗的前景
Antibiotics (Basel). 2022 Sep 6;11(9):1204. doi: 10.3390/antibiotics11091204.
8
Biofilm Formation and Antimicrobial Susceptibility of Associated With Colibacillosis Outbreaks in Broiler Chickens From Saskatchewan.与萨斯喀彻温省肉鸡大肠杆菌病暴发相关的生物膜形成及药敏性
Front Microbiol. 2022 Jun 17;13:841516. doi: 10.3389/fmicb.2022.841516. eCollection 2022.
9
Genome Sequence Analysis and Characterization of Shiga Toxin 2 Production by O157:H7 Strains Associated With a Laboratory Infection.基因组序列分析及与实验室感染相关 O157:H7 株产志贺毒素 2 的特征研究
Front Cell Infect Microbiol. 2022 Jun 13;12:888568. doi: 10.3389/fcimb.2022.888568. eCollection 2022.
10
One Day in Denmark: Comparison of Phenotypic and Genotypic Antimicrobial Susceptibility Testing in Bacterial Isolates From Clinical Settings.丹麦的一天:临床分离细菌菌株表型与基因型抗菌药物敏感性试验的比较
Front Microbiol. 2022 Jun 10;13:804627. doi: 10.3389/fmicb.2022.804627. eCollection 2022.